ArticleFrontiers in psychiatry2022
Identification of molecular signatures associated with sleep disorder and Alzheimer's disease.
Article in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Stabilization of HSP70 by deubiquitinase OTUB1 attenuates sleep deprivation-induced cognitive impairment in mice.Journal of physiology and biochemistry · 2026Article
- Single-Nucleus Landscape of Glial Cells and Neurons in Alzheimer's Disease.Molecular neurobiology · 2025Article
- A network analysis of gene co-expression in post-mortem brain tissues identifying novel genes and biological pathways underlying major depression.Frontiers in psychiatry · 2025Article
- Inflammatory and Redox Blood Gene Expression Fingerprint of Severe Obstructive Sleep Apnoea in Patients With Mild Alzheimer's Disease.Journal of inflammation research · 2025Article
- Exploring Potential Mechanisms of Sleep Disorders in Alzheimer's Dementia: A Scoping Review.Cureus · 2025Review
- Integrated bulk and single-cell profiling characterize sphingolipid metabolism in pancreatic cancer.BMC cancer · 2024Article
- Sporadic Amyotrophic Lateral Sclerosis Skeletal Muscle Transcriptome Analysis: A Comprehensive Examination of Differentially Expressed Genes.Biomolecules · 2024Review
- Identification of novel hub genes for Alzheimer's disease associated with the hippocampus using WGCNA and differential gene analysis.Frontiers in neuroscience · 2024Article
- Identification of altered immune cell types and molecular mechanisms in Alzheimer's disease progression by single-cell RNA sequencing.Frontiers in aging neuroscience · 2024Article
- Single-cell analysis identified key macrophage subpopulations associated with atherosclerosis.Open medicine (Warsaw, Poland) · 2024Article
- A review and analysis of key biomarkers in Alzheimer's disease.Frontiers in neuroscience · 2024Review
- Exploration of novel biomarkers in Alzheimer's disease based on four diagnostic models.Frontiers in aging neuroscience · 2023Article
- Article
- CLPP inhibition triggers apoptosis in human ovarian granulosa cellsFrontiers in genetics · 2023Article
- Respiratory therapies for Amyotrophic Lateral Sclerosis: A state of the art review.Chronic respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) and sleep disorders are both neurodegenerative conditions characterized by impaired or absent sleep. However, potential common pathogenetic mechanisms of these diseases are not well characterized. Methods: Differentially expressed genes (DEGs) were identified using publicly available human gene expression profiles GSE5281 for AD and GSE40562 for sleep disorder. DEGs common to the two datasets were used for enrichment analysis, and we performed multi-scale embedded gene co-expression network analysis (MEGENA) for common DEGs. Fast gene set enrichment analysis (fGSEA) was used to obtain common pathways, while gene set variation analysis (GSVA) was applied to quantify those pathways. Subsequently, we extracted the common genes between module genes identified by MEGENA and genes of the common pathways, and we constructed protein-protein interaction (PPI) networks. The top 10 genes with the highest degree of connectivity were classified as hub genes. Common genes were used to perform Metascape enrichment analysis for functional enrichment. Furthermore, we quantified infiltrating immune cells in patients with AD or sleep disorder and in controls. Results: DEGs common to the two disorders were involved in the citrate cycle and the HIF-1 signaling pathway, and several common DEGs were related to signaling pathways regulating the pluripotency of stem cells, as well as 10 other pathways. Using MEGENA, we identified 29 modules and 1,498 module genes in GSE5281, and 55 modules and 1,791 module genes in GSE40562. Hub genes involved in AD and sleep disorder were ATP5A1, ATP5B, COX5A, GAPDH, NDUFA9, NDUFS3, NDUFV2, SOD1, UQCRC1, and UQCRC2. Plasmacytoid dendritic cells and T helper 17 cells had the most extensive infiltration in both AD and sleep disorder. Conclusion: AD pathology and pathways of neurodegeneration participate in processes contributing in AD and sleep disorder. Hub genes may be worth exploring as potential candidates for targeted therapy of AD and sleep disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.